HLS Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
HLS Therapeutics has a total shareholder equity of $89.1M and total debt of $84.4M, which brings its debt-to-equity ratio to 94.7%. Its total assets and total liabilities are $197.8M and $108.7M respectively.
Key information
94.7%
Debt to equity ratio
US$84.36m
Debt
| Interest coverage ratio | n/a |
| Cash | US$19.44m |
| Equity | US$89.07m |
| Total liabilities | US$108.69m |
| Total assets | US$197.75m |
Recent financial health updates
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14Recent updates
Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
May 12After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22HLS Therapeutics (TSE:HLS) Will Pay A Dividend Of CA$0.05
Nov 29HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Aug 10Financial Position Analysis
Short Term Liabilities: HLS's short term assets ($40.8M) exceed its short term liabilities ($26.2M).
Long Term Liabilities: HLS's short term assets ($40.8M) do not cover its long term liabilities ($82.5M).
Debt to Equity History and Analysis
Debt Level: HLS's net debt to equity ratio (72.9%) is considered high.
Reducing Debt: HLS's debt to equity ratio has increased from 62.3% to 94.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HLS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HLS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 7.7% per year.